Regentis Biomaterials Ltd. (RGNT) shareholders
RGNTNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Feb 24, 2026Score 1/30
$1.14−0.08 (-6.56%)
Close on Nov 18, 2026Market cap $5.90MP/E –Yield –
Ownership
Who owns Regentis Biomaterials's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rosalind Advisors, Inc. Joint filing with Salamon Steven A J (9.90%), Aharon Gil (9.90%) and 1 more | 1,428,570 | 9.90% | 13G (passive) | Jun 30, 2026 |
| Dr. Ehud Geller Joint filing with Medica III Investments (International) L.P. (23.20%), Medica III Investments (Israel) L.P. (23.20%) and 4 more | 1,332,867 | 23.20% | 13G (passive) | Dec 31, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ehud Geller | Chief Executive Officer, Director | – | – | Jul 13, 2026 |
| Galit Reske | Chief Medical Officer | – | – | Mar 30, 2026 |
| Arie Gordashnikov | Chief Accounting Officer | – | – | Mar 18, 2026 |
| Ori Gon | Chief Financial Officer | – | – | Mar 18, 2026 |
| Susan PHD Alpert MD | Director | – | – | Jul 13, 2026 |
| Pini Ben-Elazar | Director | 128,666 | 2.48% | Jul 13, 2026 |
| Efraim Cohen-Arazi | Director | – | – | Jul 13, 2026 |
| Jeff Dykan | Director | 270,473 | 5.22% | Jul 13, 2026 |
| Keith Valentine | Director | – | – | Jul 13, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.19%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-46.0%
From 0M shares
Short volume, 20 days
42.8%
Of volume reported to FINRA
Shares sold short, last 11 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Regentis Biomaterials's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,363 shares on Oct 6, 2026 over the last 90 days.
See a number that looks wrong?